3-溴-5-甲基吡啶甲酸 | 1211515-68-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-溴-5-甲基吡啶甲酸
• 中文别名: 3-溴-5-甲基吡啶-2-羧酸
• 英文名称: 3-bromo-5-methyl-pyridine-2-carboxylic acid
• 英文别名: 3-bromo-5-methylpicolinic acid；3-Bromo-5-methylpyridine-2-carboxylic acid
• CAS: 1211515-68-2
• 化学式: C₇H₆BrNO₂
• 分子量: 216.034
• InChiKey: BAFGEDISONEYIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  3-溴-5-甲基吡啶甲酸 在 三乙烯二胺 、 copper(l) iodide 、 2,2,6,6-四甲基-3,5-庚二酮 、 硫酸 、 乙酸酐 、 三溴化硼 、 二异丁基氢化铝 、 caesium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 45.5h， 生成 8-(2-hydroxyphenoxy)-6-methylindolizine-2-carbonitrile
  参考文献：
  名称：

  Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group

  摘要：

  Members of the catechol diether class are highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). The most active compounds yield EC50 values below 0.5 nM in assays using human T-cells infected by wild-type HIV-1. However, these compounds such as rilpivirine, the most recently FDA-approved NNRTI, bear a cyanovinylphenyl (CVP) group. This is an uncommon substructure in drugs that gives reactivity concerns. In the present work, computer simulations were used to design bicyclic replacements for the CVP group. The predicted viability of a 2-cyanoindolizinyl alternative was confirmed experimentally and provided compounds with 0.4 nM activity against the wild-type virus. The compounds also performed well with EC50 values of 10 nM against the challenging HIV-1 variant that contains the Lys103Asn/Tyr181Cys double mutation in the RT enzyme. Indolyl and benzofuranyl analogues were also investigated; the most potent compounds in these cases have EC50 values toward wild-type HIV-1 near 10 nM and high-nanomolar activities toward the double-variant. The structural expectations from the modeling were much enhanced by obtaining an X-ray crystal structure at 2.88 Å resolution for the complex of the parent 2-cyanoindolizine 10b and HIV-1 RT. The aqueous solubilities of the most potent indolizine analogues were also measured to be ~40 μg/mL, which is similar to that for the approved drug efavirenz and ~1000-fold greater than for rilpivirine.

  DOI：

  10.1021/ja408917n

文献信息

• COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS
  申请人：YALE UNIVERSITY

  公开号：US20150105351A1

  公开（公告）日：2015-04-16

  The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.

  本发明涉及新型纳摩尔和皮摩尔HIV逆转录酶抑制剂，以及由此制备的药物组合物和用于抑制逆转录酶和治疗HIV感染的方法，特别包括对HIV-1和HIV-2的耐药菌株以及作为HIV感染后果发生的次生疾病状态和/或条件。
• [EN] COMPOUNDS FOR THE TREATMENT OF HIV<br/>[FR] COMPOSÉS POUR TRAITER LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2013006738A1

  公开（公告）日：2013-01-10

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供了如下式（I）的化合物或其盐，还提供了包含如下式（I）化合物的药物组合物，制备如下式（I）化合物的方法，用于制备如下式（I）化合物的中间体以及治疗Retroviridae病毒感染的治疗方法，包括由HIV病毒引起的感染。
• SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20160075696A1

  公开（公告）日：2016-03-17

  The present invention is directed to compounds of Formula I: Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：还描述了制备式I化合物的方法。该发明还涉及包含式I化合物的药物组合物。使用本发明化合物的方法也在本发明的范围内。
• [EN] NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES<br/>[FR] NOUVEAUX N-[(HÉTÉROARYLOXY)PROPANYL]HÉTÉROARYL CARBOXAMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2017178344A1

  公开（公告）日：2017-10-19

  This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 and Ar2 have meanings given in the description.

  本发明涉及式(I)的化合物，其制备方法，含有这些化合物的药物组合物以及它们在与促嗜睡素亚型1受体相关的疾病治疗中的应用。Ar1和Ar2的含义见描述。
• COMPOUNDS FOR THE TREATMENT OF HIV
  申请人：Bondy Steven S.

  公开号：US20140142085A1

  公开（公告）日：2014-05-22

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供了以下式子（I）的化合物或其盐，如本文所述。本发明还提供了包括式子（I）化合物的制药组合物，制备式子（I）化合物的方法，用于制备式子I化合物的中间体以及治疗逆转录病毒感染的治疗方法，包括由HIV病毒引起的感染。